Nerve damage may raise stomach risks for diabetes drug users
NCT ID NCT07156591
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 31 times
Summary
This study will observe 460 diabetic patients who take semaglutide to see if those with nerve damage (neuropathy) are more likely to develop gastric retention, where the stomach doesn't empty properly. Researchers will compare patients with and without neuropathy during routine endoscopies. The goal is to better understand who might be at higher risk for this side effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huadong hospital, Fudan university
Shanghai, Shanghai Municipality, 200040, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.